Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin Maintenance After WBRT for Lung Cancer Brain Metastases
NCT00415363Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2006
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in brain metastases comparing Enzastaurin with Placebo (2 arms). Primary endpoint: Time to Progression of Brain Metastases up to 21.2 months. Started Dec 2006; status: completed.
02
Drugs
enzastaurin
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT00415363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415363.